Next Article in Journal
Factors Influencing the Knowledge Gap regarding Influenza and Influenza Vaccination in the Context of COVID-19 Pandemic: A Cross-Sectional Survey in China
Previous Article in Journal
Design, Characterization, and Immune Augmentation of Docosahexaenoic Acid Nanovesicles as a Potential Delivery System for Recombinant HBsAg Protein
Previous Article in Special Issue
Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
Vaccines
Volume 10
Issue 6
10.3390/vaccines10060956
vaccines-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants

by
Yuntao Zhang
1,
Wenjie Tan
2,
Zhiyong Lou
3,
Baoying Huang
2,
Weimin Zhou
2,
Yuxiu Zhao
4,
Jin Zhang
4,
Hongyang Liang
4,
Na Li
4,
Xiujuan Zhu
4,
Ling Ding
4,
Yancen Guo
4,
Zhenyu He
4,
Yao He
4,
Zhanhui Wang
4,
Bo Ma
4,
Meng Ma
4,
Suhua Zhao
4,
Zhen Chang
4,
Xue Zhao
4,
Xiaotong Zheng
4,
Guizhen Wu
2,*,
Hui Wang
4,* and
Xiaoming Yang
1,*add Show full author list remove Hide full author list
1
China National Biotec Group Company Limited, Beijing 100024, China
2
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
3
MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University, Beijing 100084, China
4
Beijing Institute of Biological Products Company Limited, Beijing 100176, China
*
Authors to whom correspondence should be addressed.
Academic Editor: Fernando Rodríguez González
Vaccines 2022, 10(6), 956; https://doi.org/10.3390/vaccines10060956
Received: 23 May 2022 / Revised: 13 June 2022 / Accepted: 14 June 2022 / Published: 16 June 2022
(This article belongs to the Special Issue Advances in COVID-19 Vaccines Development)
View Full-Text Download PDF
Browse Figures

Abstract

It has been reported that the novel coronavirus (COVID-19) has caused more than 286 million cases and 5.4 million deaths to date. Several strategies have been implemented globally, such as social distancing and the development of the vaccines. Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have appeared, such as Alpha, Beta, Gamma, Delta, and Omicron. With the rapid spread of the novel coronavirus and the rapidly changing mutants, the development of a broad-spectrum multivalent vaccine is considered to be the most effective way to defend against the constantly mutating virus. Here, we evaluated the immunogenicity of the multivalent COVID-19 inactivated vaccine. Mice were immunized by multivalent COVID-19 inactivated vaccine, and the neutralizing antibodies in serum were analyzed. The results show that HB02 + Delta + Omicron trivalent vaccine could provide broad spectrum protection against HB02, Beta, Delta, and Omicron virus. Additionally, the different multivalent COVID-19 inactivated vaccines could enhance cellular immunity. Together, our findings suggest that the multivalent COVID-19 inactivated vaccine can provide broad spectrum protection against HB02 and other virus variants in humoral and cellular immunity, providing new ideas for the development of a broad-spectrum COVID-19 vaccine. View Full-Text
Keywords: Beta; Delta; HB02; immunogenicity; multivalent inactivated vaccines; Omicron; SARS-CoV-2 Beta; Delta; HB02; immunogenicity; multivalent inactivated vaccines; Omicron; SARS-CoV-2
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Zhang, Y.; Tan, W.; Lou, Z.; Huang, B.; Zhou, W.; Zhao, Y.; Zhang, J.; Liang, H.; Li, N.; Zhu, X.; Ding, L.; Guo, Y.; He, Z.; He, Y.; Wang, Z.; Ma, B.; Ma, M.; Zhao, S.; Chang, Z.; Zhao, X.; Zheng, X.; Wu, G.; Wang, H.; Yang, X. Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. Vaccines 2022, 10, 956. https://doi.org/10.3390/vaccines10060956

AMA Style

Zhang Y, Tan W, Lou Z, Huang B, Zhou W, Zhao Y, Zhang J, Liang H, Li N, Zhu X, Ding L, Guo Y, He Z, He Y, Wang Z, Ma B, Ma M, Zhao S, Chang Z, Zhao X, Zheng X, Wu G, Wang H, Yang X. Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. Vaccines. 2022; 10(6):956. https://doi.org/10.3390/vaccines10060956

Chicago/Turabian Style

Zhang, Yuntao, Wenjie Tan, Zhiyong Lou, Baoying Huang, Weimin Zhou, Yuxiu Zhao, Jin Zhang, Hongyang Liang, Na Li, Xiujuan Zhu, Ling Ding, Yancen Guo, Zhenyu He, Yao He, Zhanhui Wang, Bo Ma, Meng Ma, Suhua Zhao, Zhen Chang, Xue Zhao, Xiaotong Zheng, Guizhen Wu, Hui Wang, and Xiaoming Yang. 2022. "Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants" Vaccines 10, no. 6: 956. https://doi.org/10.3390/vaccines10060956

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop